UNSPSC 51162305: Acetaminophen/caffeine/chlorpheniramine/phenylephrine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51162305 Acetaminophen/caffeine/chlorpheniramine/phenylephrine/pyrilamine is a Commodity code that captures pharmaceutical products for state and local healthcare and emergency-response procurement, though recent opportunities tagged under this code show minimal alignment with the specific combination product name. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026, seeking parenteral products, services, and equipment—including parenteral nutrition solutions, intravenous solutions, and controlled substances for incarcerated individuals—due October 7, 2026, with a pre-bid conference on September 23, 2026. The contract spans eight correctional facilities across three regions and anticipates awarding up to three bidders per region through November 26, 2026, to June 30, 2030, with fixed pricing required for the initial two-year term. Separately, Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries. Issuing bodies include state corrections agencies and county public-health authorities, with participation encouraged from small businesses, minority-owned businesses, women-owned businesses, and veteran-owned businesses under applicable state set-aside programs where the source names them. Washington State imposes a 5% Small and Diverse Business Goal and requires Subcontractor Inclusion Plans identifying qualified minority-owned, women-owned, and disadvantaged businesses where economically prudent.

Recent activity appears concentrated in Washington and Florida, with the Washington State Department of Corrections as a significant buyer of parenteral products with strict same-day and 24-hour delivery windows tied to inmate healthcare operations. The code itself bears limited relevance to the actual solicitations posted under it—neither the Washington parenteral-products contract nor the Seminole County naloxone procurement aligns with the code's nominal scope of a specific acetaminophen-based combination drug. State and local procurement records tagged under this code show activity in pharmaceutical supply chains for correctional and emergency-response contexts rather than the targeted product named in the code's definition. Contractors pursuing opportunities in this space face stringent insurance requirements, compliance with state business-licensing and background-clearance standards, and in the Washington case, documented experience with intravenous preparation and delivery under tight operational windows.